Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/22/26 | Roche (RO) | giredestrant for Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/22/26 | Roche (RO) | giredestrant for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/21/26 | Roche (RO) | giredestrant for Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/21/26 | Roche (RO) | giredestrant for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/21/26 | Eli Lilly and Company (LLY) | retatrutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |